CMS RBCS · Tests · General Laboratory

Drug Tests codes

8 CPT®/HCPCS codes, ranked by est. all-Medicare services — scaled from national Medicare Part B fee-for-service volume. Open any code for the full market view — ranked physician groups, geography, and 12-year trend.

CY2024 · National scale is an all-Medicare estimate · est. — scaled estimate — assumes MA utilization mirrors FFS; not an observation; the observed fee-for-service figure is shown adjacent. Part B · national figures

HCPCS · General Laboratory test G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms CMS descriptor · HCPCS
Medicare Part B claims

First observed 2016 — first year this code appears in Part B claims

National scale 1.27M services · est. ▲ 1.4% YoY · 343,271 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 616,141 observed fee-for-service services

See the national market for G0480 → ranked groups · states · 12-yr trend

HCPCS · General Laboratory test G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms CMS descriptor · HCPCS
Medicare Part B claims

First observed 2016 — first year this code appears in Part B claims

National scale 1.10M services · est. ▼ 6.3% YoY · 278,929 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 537,743 observed fee-for-service services

See the national market for G0483 → ranked groups · states · 12-yr trend

HCPCS · General Laboratory test G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms CMS descriptor · HCPCS
Medicare Part B claims

First observed 2016 — first year this code appears in Part B claims

National scale 1.00M services · est. ▼ 9.5% YoY · 268,354 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 489,866 observed fee-for-service services

See the national market for G0482 → ranked groups · states · 12-yr trend

HCPCS · General Laboratory test G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms CMS descriptor · HCPCS
Medicare Part B claims

First observed 2016 — first year this code appears in Part B claims

National scale 926,681 services · est. ▲ 5.8% YoY · 259,038 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 455,037 observed fee-for-service services

See the national market for G0481 → ranked groups · states · 12-yr trend

HCPCS · General Laboratory test G0659 Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any CMS descriptor · HCPCS
Medicare Part B claims

First observed 2017 — first year this code appears in Part B claims

National scale 796 services · est. ▼ 27.8% YoY · 155 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 397 observed fee-for-service services

See the national market for G0659 → ranked groups · states · 12-yr trend

3 more CPT-coded procedures — shown with a trial or subscription, under AMA licensing.